Vera Therapeutics insider plans $2.2M share sale

Vera Therapeutics, Inc. (VERA) received a notice that stockholder Marshall Fordyce intends to sell up to 64,750 shares of common stock under Rule 144.

Rhea-AI Filing Summary

Vera Therapeutics, Inc. (VERA) received a notice that stockholder Marshall Fordyce intends to sell up to 64,750 shares of common stock under Rule 144. The shares will be delivered from the exercise of stock options for cash through Morgan Stanley Smith Barney, with sales noted as of September 2, 2026 on NASDAQ.

The notice also lists prior Rule 10b5-1 plan sales of Vera Therapeutics common stock by Marshall Fordyce over the past three months.

Key Figures

Planned shares to be sold: 64,750 shares Planned sale value: $2,216,392.50 Shares sold July 7, 2026: 46,250 shares +3 more

6 metrics

Planned shares to be sold 64,750 shares Common stock sale under Rule 144 noted as of September 2, 2026

Planned sale value $2,216,392.50 Aggregate value reported for 64,750 Vera Therapeutics common shares

Shares sold July 7, 2026 46,250 shares Rule 10b5-1 sale of Vera Therapeutics common stock

Proceeds July 7, 2026 sale $1,956,186.30 Rule 10b5-1 sale of 46,250 common shares

Shares sold June 23, 2026 18,500 shares Rule 10b5-1 sale of Vera Therapeutics common stock

Proceeds June 23, 2026 sale $701,767.90 Rule 10b5-1 sale of 18,500 common shares

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options, Common

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for MARSHALL FORDYCE 2000 Sierra Point Parkway"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/02/2026 | Exercise of Stock Options | Issuer"

Common financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing reveal about planned insider sales for VERA?

The notice states that Marshall Fordyce plans to sell up to 64,750 shares of Vera Therapeutics common stock, with the shares to be obtained via the exercise of stock options for cash and sold through Morgan Stanley Smith Barney on or after September 2, 2026.

How many VERA shares has Marshall Fordyce sold in the last three months?

The filing lists two past Rule 10b5-1 sales: 46,250 shares of Vera Therapeutics common stock on July 7, 2026 for $1,956,186.30 and 18,500 shares on June 23, 2026 for $701,767.90.

What is the total value of the VERA shares Marshall Fordyce plans to sell under the new Form 144?

For the planned sale of 64,750 shares of Vera Therapeutics common stock, the filing reports an aggregate value of $2,216,392.50, based on the information given in the securities section of the notice.

How will the planned VERA share sale be funded and settled?

The filing states that the Vera Therapeutics shares to be sold were and will be received upon the exercise of stock options, with the method of acquisition shown as “Cash,” meaning the options are to be exercised for cash and the resulting shares sold.

On which market are the VERA shares in this Form 144 expected to be sold?

The Form 144 identifies the market for the Vera Therapeutics common stock as NASDAQ, indicating that the contemplated sales of the 64,750 shares are expected to occur on that exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:34 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:32 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001859453
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERA THERAPEUTICS INC
SEC File Number	001-40407
Address of Issuer	2000 Sierra Point Parkway, Suite 1200 Brisbane CALIFORNIA 94005
Phone	6507700077
Name of Person for Whose Account the Securities are To Be Sold	MARSHALL FORDYCE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	64750	2216392.50	72063335	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Exercise of Stock Options	Issuer			64750	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MARSHALL FORDYCE 2000 Sierra Point Parkway, Suite 1200 Brisbane CA 94005	Common	07/07/2026	46250	1956186.30
10b5-1 Sales for MARSHALL FORDYCE 2000 Sierra Point Parkway, Suite 1200 Brisbane CA 94005	Common	06/23/2026	18500	701767.90

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Marshall Fordyce
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)